BioLineRx announces USD6m direct offering
Categories: Capital Markets
Israel-based BioLineRX, a biopharmaceutical company traded in both Israel and the U.S., has announced a USD6m registered direct offering, with the transaction led by
Greenberg Traurig. Tel Aviv shareholder Gary Emmanuel, with support from Devora Snyder-Shefer and Michael Soumas, advised the company, which is in the commercial stage and is pursuing life-changing therapies for certain cancers and rare diseases.